

2nd Survey on HH-treatment (July 2010)

Dr Françoise COURTOIS

Nijmeguen - EFAPH General Meeting September 18th 2010

Outline

- 1. Aims
- 2. Methodology
- 3. Results
- 4. Conclusions

AIMS

- 1. Reiterate the survey on HH treatment and compare the results with those presented in 2007 in London with the same topics:
 - phlebotomies
 - usual costs
 - disposal of removed blood

2. Highlight topics which arouse a discussion with EFAPH members and in consequence to create some working groups in 2011

Methodology


• May 2010: review of the 1st questionnary, 6 topics were retained (few modifications)

• <u>June 2010</u>: the questionnaire was dispatched to the presidents of 11 EFAPH members + 1 country not yet in EFAPH (Austria)

• September 2010: feedback and analysis

General results

- 12 countries investigated
- 8 responses for:
 - "Whole" country: 3
 - Part of the country : 5



	Inhab. (millions)	App. survey coverage (%)
Germany	82	100
Norway	5	100
Spain	39	100
Hungary	10	75
Ireland	4	75
Belgium	10	50
France	58	50
Portugal	10	25
TOTAL	218	

^{*} Approximatively 60.000 HFE 282Y/282Y

(1) Where does the treatment usually take place?

100% in an hospital (Day hospital): 1/8 countries (Spain)

100 % in a Blood Center:
 1/8 countries (Hungary)

Several locations :

Day hospital + Blood center :

Hospital + Blood center:

Day hospital + Blood center + gen. practionner

 Hospital + Blood center + mobile nursing unit (at home) and nursing center + Medical laboratories... 2/8 countries (Belgium, Portugal)

1/8 countries (Norway)

2/8 countries (Germany, Ireland)

- 1/8 countries (France)

Check up (consultation) before phlebotomy

	Each time	Variable	No response
Medical practionner		2 Hungary, Spain	
Nurse		2 Portugal, Belgium	
Med.Pract + Nurse	1 France	1 Germany	
Not specified		1 Norway	1 Ireland

Biological ckeck-up before each phlebotomy?

	No response	Each time	Variable frequency	Seldom
НЬ		6	2 Belgium, Spain	
Only Ferritin	1 Spain	1 Ireland	6	
Fer + Trf sat	3 Belgian, France Ireland		4 Portugal, Hungary, Norway, Spain	1 Germany

(3) Phlebotomy cost for patients...

	Countries (N)		
Free	4	Spain, Por Hungary	tugal, Germany,
Heterogenous costs	4	France Ireland Norway Belgium	14.77 € -> ??? variable free -> 750 € free -> 38 € free -> 3 €

(4) Cell apheresis as an alternative treatment?

Yes	5
but occasionally	Germany, France, Hungary, Norway, Belgium
No	1
	Ireland
No response	2
	Portugal, Spain

(5) Is the volume of blood removed quantified?

		Adapted?	Not every time
No	1 Spain		
Yes	7	5 France, Belgium, Portugal, Hungary, Ireland)	2 Germany, Norway

The interpretation of the answers was difficult because of a misunderstanding in the question

(6) Is blood removed used for transfusion?

Yes	2
	France, Portugal
Variable in the country	3 Germany, Ireland, Norway
No (but probably a national issue)	3 Hungary, Belgium, Spain

Conclusions (I)

1. Take the results with precaution:

- The answers reflect mainly the presidents' experiences,
- Therefore the answers do not cover the whole country and we suppose it will be necessary to do regional surveys in each country,
- The answers are more subjective than quantitative but probably caused by unclear expression and misunderstanding

2. The responses of this survey have concerned an european population of 170 Mio habitants, representing approximately 60.000 HH homozygotes...

Conclusions (II)

3. It is interesting to note that the HH patients can be treated in several places:

Hospital (day hospital,...)
Blood centre
General practioner office
Mobile nursing unit
Medical laboratories

Other solutions probably exist, but all must respect good clinical practices!

Conclusions (III)

- 4. A consultation before phlebotomy is carried out in 7 countries
 - either by a medical doctor or by a nurse or both and the frequency is variable
- 5. A biological test is organized before phlebotomy in 7 countries
 - Hemoglobine is tested each time in 6 out of 7 countries
 - Ferritine is tested each time in1 country and variably in the others countries
 - Ferritine + Trf saturation tests are completely variable in 5 countries

A future EFAPH discussion?

Which questions are worthwhile investigating?

- Who is doing the consultation?
- Which frequency?
- Which biological tests?
- Which frequency?

Conclusions (IV)

6. Few countries set up rules concerning the use of blood from HH patients for transfusion



This subject is of major interest in most countries and 4 countries expressed that this topic must be handled by EFAPH

3 countries are ready to be part in a working group!

Portugal Hungary Norway

Thank you everybody!